,7 Compared with those in healthy individuals and patients with benign pancreatic disease, Gal-3 expression levels are significantly higher in pancreatic cancer tissues and patient sera, providing evidence for its use as a potential biomarker.8 This evidence concerns the gene LGALS3 and pancreatic neoplasm.